News & Updates
Filter by Specialty:
OnabotulinumtoxinA as effective as, safer than pharmacotherapy for OAB
Women with refractory overactive bladder (OAB) may improve their symptoms by using either intradetrusor onabotulinumtoxinA or combined pharmacotherapy with solifenacin and mirabegron, suggests a study.
OnabotulinumtoxinA as effective as, safer than pharmacotherapy for OAB
02 Oct 2025
JAK inhibitor a new hope for new-onset T1D?
The 2-year outcomes from the phase II BANDIT* trial confirm the potential of the Janus kinase (JAK) inhibitor baricitinib for the treatment of new-onset type 1 diabetes (T1D).
JAK inhibitor a new hope for new-onset T1D?
02 Oct 2025
Dose reduction does not limit efficacy of trastuzumab deruxtecan in MBC
Reducing the dose of trastuzumab deruxtecan (T-DXd) does not have any significant effect on real-world (rw) progression-free survival (PFS) or treatment-related toxicities among patients with metastatic breast cancer (MBC), as shown in a Singapore study.
Dose reduction does not limit efficacy of trastuzumab deruxtecan in MBC
01 Oct 2025
Long COVID symptoms may persist 3 years post-infection
One in five COVID-19 survivors experiences at least one unresolved symptom 3 years after the initial infection, a systematic review and meta-analysis reports.